Stifel analyst Benjamin Burnett lowered the firm’s price target on Repare Therapeutics (RPTX) to $4 from $9 and keeps a Buy rating on the shares after updated results for camonsertib plus lunresertib came in below expectations. The firm expects the debate after the data to focus on the likelihood of success in endometrial cancer and for continued scrutiny of the balance sheet, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Closing Bell Movers: RH soars 20% on earnings, guidance raise
- Repare Therapeutics Shows Promise in Cancer Drug Trials
- Repare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trial
- Repare Therapeutics announces CRADA to advance camonsertib development
- Repare Therapeutics Reports Q3 2024 Progress and Outlook